Comparative Pharmacology
Head-to-head clinical analysis: E MYCIN E versus PROKLAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E MYCIN E versus PROKLAR.
E-MYCIN E vs PROKLAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation of peptide chains.
PROKLAR (clarithromycin) is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide chain elongation.
250-500 mg orally every 6 hours or 333-500 mg every 8 hours; maximum 4 g/day.
500 mg orally every 12 hours for 7-14 days.
None Documented
None Documented
Terminal elimination half-life is 1.5-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment.
Terminal elimination half-life: 2-4 hours (prolonged to 6-8 hours in hepatic impairment); context: requires q8-12h dosing in normal renal function
Primarily excreted unchanged in urine (70-80%) via glomerular filtration and tubular secretion; 15-20% excreted in feces via biliary elimination.
Renal: 20-30% unchanged; fecal: 15-30%; biliary: 5-10%; total renal excretion of metabolites: ~70%
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic